For Immediate Release
December 16, 2025
CRANFORD, NJ — OYE Therapeutics, a clinical-stage pharmaceutical company developing a novel high-concentration caffeine platform, announced the successful completion of a $5.475 million Series A financing to advance clinical development for anesthesia recovery and opioid-induced respiratory depression (OIRD).
The financing will support the company’s planned Phase 1 clinical trial, expected to begin in Q1 2026. OYE’s investigational intravenous formulation is designed to rapidly stimulate the central nervous system and respiratory drive by blocking adenosine signaling, without relying on opioid antagonism.
In overdose settings, OYE’s approach is intended to complement naloxone by helping patients remain awake longer and breathe more consistently during recovery. The platform also has potential applications in general anesthesia recovery and acute care settings where faster emergence and improved respiratory support are critical.
WBB Securities LLC acted as the placement agent for the Series A financing.
Read the full press release:
https://oyetherapeutics.reportablenews.com/pr/oye-raises-5-475-million-series-a
About WBB Securities
WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily on the life sciences niche. Established in 2001 with offices in New Jersey, New York, and California. WBB Securities is registered with the SEC as a broker-dealer, a member of FINRA, and a state-registered investment advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.
About OYE Therapeutics
OYE Therapeutics is a clinical-stage pharmaceutical development company focused on transforming overlooked or “accepted-as-intractable” clinical problems into solvable challenges. Developing a differentiated, platform designed to accelerate recovery from anesthesia and deep sedation and address fentanyl-related intoxication through a novel mechanism distinct from naloxone. Our mission is to improve existing treatments through breakthrough enhancements that target serious unmet needs in patient care. The name OYE stands for “Open Your Eyes” — a phrase that reflects both the clinical necessity and metaphorical vision that inspired our founding. It underscores our belief that some of the most important progress in healthcare comes from rethinking problems others have resigned to live with.
